Geistlich vallomix™: Osteoinductivity and Volume Stability in One Package
Since recently introducing vallomix™, the first xenogeneic/allogeneic validated bone substitute, Geistlich has clinicians both intrigued and "more than pleased." The innovative product combines the verified osteoinductivity of vallos™ allograft with the proven volume stability of Bio-Oss®for "best of both worlds" results, providing optimal consistency and performance in challenging clinical situations.
Liliana Aranguren, DDS, MDSc, says utilizing the latest, clinically proven technologies in the dental industry is a top priority for her team at South Florida Center for Periodontics & Implant Dentistry in Boca Raton. Aranguren, who is board certified in periodontics and dental implant surgery by the American Board of Periodontology, specializes in minimally invasive tissue grafting, laser-assisted periodontal treatment, immediate load implant dentistry, accelerated orthodontics, and esthetic enhancements, and is now a proponent of vallomix.
"Having the option of mixing an allograft that offers osteoinduction with a xenograft that preserves volume is a perfect combination, both for my treatment needs and patients," she says. "It's a reliable system for rapidly restoring vital bone with long-term volume stability that offers easy handling in demanding clinical scenarios. I recently re-entered treated sites, and the bone volume was consistently abundant. I am more than pleased with the experience I have had to date."
Geistlich's vallomix conveniently packages Bio-Oss granules and vallos granules and fibers. The bone augmentation materials can be mixed or layered. Irina F. Dragan, DDS, DMD, MS, of Brookline Periodontal Associates in Brookline, Massachusetts, and who is board certified in periodontics and dental implant surgery by the American Board of Periodontology, has completed more than a dozen vallomix cases in various therapeutic indications, including four cases that have had implants placed. "In looking at clinical and radiographic outcomes before implant placement, the healing was uneventful with no complications and soft-tissue healing was within normal limits," she reports, noting that allowing a healing time longer than 4 months was beneficial.
Dragan recommends clinicians consider integrating vallomix into their treatment protocols, and, as with any new material, take a step-by-step approach and follow clinical guidelines, especially with regard to the hydration of the regenerative materials.
Aranguren, who summarizes the main benefits as bone volume maintenance, osteoinductive properties, adequate formation and stability of new bone over time, and the convenience of co-packaging, believes vallomix will become a go-to product for clinicians in many types of cases. "Whether it's for an extraction socket, periodontal defect, sinus lift, or implant surgery, Geistlich's vallomix is a superior product," she attests.
Liliana Aranguren, DDS, MDSc
Private Practice, Boca Raton, Florida; Diplomate, American Academy of Periodontology; Fellow, International Team for Implantology
Irina F. Dragan, DDS, DMD, MS
Private Practice, Brookline, Massachusetts; Senior Clinical Sciences Manager, Geistlich Biomaterials
Geistlich Pharma North America, Inc.